PHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma Inc., and BioCelerate announce that its new
technology platform, DataCelerateTM, is live and accessible
to participating TransCelerate and BioCelerate Member Companies. The
global platform allows for multiple de-identified research and
development data types to be submitted, uploaded, converted, harmonized,
and downloaded through an access controlled, secured environment.

Mike Graziano, PhD, Vice President at Bristol-Myers Squibb and leader of
the BioCelerate Toxicology Data Sharing Initiative states, “We’ve built
DataCelerate to provide Member Companies with the opportunity to make
more informed decisions around product development, further validate key
study findings and diminish attrition earlier. It was designed to scale
various types of data and has the potential to connect with other
external existing data sources, reducing the many data silos that exist
today.”

The robust development and scalable design of DataCelerate features a
flexible single sign-on platform with an automated user interface to
quickly develop translational insights across the research and
development (R&D) continuum. The technology can support both structured
and unstructured data and is built on the Accenture Insights Platform
(AIP) by Accenture Applied Intelligence to provide dynamic search,
analytics, visualization and reporting.

“TransCelerate and BioCelerate Members envisioned a solution that would
enable collaboration and sharing of R&D data,” notes Dalvir Gill, PhD,
CEO of TransCelerate BioPharma, Inc. “We see the value of this system
only growing as we increase data volume, expand data types and over time
provide the ability for these disparate forms of data to connect within
disease areas or drug classes.”

Dr. Gill also shared, “With a future vision of linking de-identified,
clean and converted data across the entire R&D continuum, the innate
flexibility and modularity of the underlying data lake will serve as a
foundation for future TransCelerate clinical data and preclinical
contributions, expediting the discovery of translational insights and
predictive outcomes in order to bring new medicines to patients faster.”

Currently, the first data set - preclinical toxicology data - is live
and accessible in DataCelerate. TransCelerate’s Placebo and Standard of
Care (PSoC) data repository will be migrated into DataCelerate,
expanding the volume of data to include over 85,000 patients and in
excess of 130 studies in nearly 20 therapeutic areas ranging from
diabetes to rare conditions such as Duchenne muscular dystrophy.

Elliott Levy, MD, Senior Vice President, Global Development at Amgen and
Chair of the TransCelerate Board of Directors commented on the
DataCelerate launch, “A number of TransCelerate Member Companies have
already experienced great benefit from having access to de-identified
historical clinical trial control data from other companies. We’ve been
able to improve our clinical trial designs, and better understand
incoming safety data. As more sponsors embrace data sharing, we have the
potential to significantly reduce randomization to placebo and standard
of care arms.” He went on, “DataCelerate offers the potential for better
predictive science and reduced patient exposure to placebo. It is also a
major step toward a more sophisticated data sharing process for all R&D
stakeholders.”

TransCelerate BioPharma Inc. is a non-profit organization dedicated to
improving the health of people around the world by simplifying and
accelerating the research and development (R&D) of innovative new
therapies. The organizations' mission is to collaborate across the
global biopharmaceutical R&D community to identify, prioritize, design,
and facilitate implementation of solutions designed to drive the
efficient, effective, and high-quality delivery of new medicines. The
vast majority of TransCelerate solutions are publicly available. The
Member Companies of TransCelerate are AbbVie, Allergan, Inc., Amgen,
Inc., Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim,
Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Inc. (a
subsidiary of Merck KGaA, Darmstadt, Germany), GlaxoSmithKline, Johnson
& Johnson, Merck & Co., Inc., Novartis, Novo Nordisk, Pfizer, the Roche
Group, Sanofi, Shionogi & Co., Ltd. and UCB.

Membership in TransCelerate is open to pharmaceutical and biotechnology
companies with Research & Development operations. Executive offices are
located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com.

About BioCelerate

BioCelerate explores areas in preclinical research that have unmet needs
that could benefit from a collaborative approach. Initiatives are
approved by a governing council made up of participating BioCelerate
Member Companies. BioCelerate is a separate legal subsidiary of
TransCelerate BioPharma with separate funding and support. The
organization is led by TransCelerate CEO, Dalvir Gill. To participate in
BioCelerate, you must be a Member Company of TransCelerate BioPharma,
Inc. For more information, please visit http://www.transceleratebiopharmainc.com/biocelerate.